Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.

Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM.

Clin Infect Dis. 2012 Jul;55(2):291-300. doi: 10.1093/cid/cis383. Epub 2012 May 1.

PMID:
22550117
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.

Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir S, Malaspina A, Morre M, Buffet R, Silvestri G, Lederman MM; ACTG 5214 Study Team.

Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20.

PMID:
19380868
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand-Fénoêl V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF.

J Clin Invest. 2009 Apr;119(4):997-1007. doi: 10.1172/JCI38052. Epub 2009 Mar 16.

PMID:
19287090
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Thymic function in HIV-infection.

Kolte L.

Dan Med J. 2013 Apr;60(4):B4622. Review.

PMID:
23651726
[PubMed - indexed for MEDLINE]
5.

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.

Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, Venzon DJ, Korngold R, Pecora A, Gress RE, Mackall CL.

J Exp Med. 2008 Jul 7;205(7):1701-14. doi: 10.1084/jem.20071681. Epub 2008 Jun 23.

PMID:
18573906
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.

Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R; AACTG 325 Protocol Team.

AIDS. 2002 May 24;16(8):1147-54.

PMID:
12004273
[PubMed - indexed for MEDLINE]
7.

Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.

Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte Ad, Galli M, Meroni L.

AIDS. 2006 Aug 22;20(13):1727-36.

PMID:
16931937
[PubMed - indexed for MEDLINE]
8.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
[PubMed - indexed for MEDLINE]
9.

Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL.

Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M.

J Infect Dis. 2000 Oct;182(4):1070-6. Epub 2000 Aug 28.

PMID:
10979901
[PubMed - indexed for MEDLINE]
Free Article
10.

Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.

Al-Harthi L, Voris J, Patterson BK, Becker S, Eron J, Smith KY, D'Amico R, Mildvan D, Snidow J, Pobiner B, Yau L, Landay A.

HIV Med. 2004 Jan;5(1):55-65.

PMID:
14731171
[PubMed - indexed for MEDLINE]
11.

Antiretroviral therapy restores diversity in the T-cell receptor Vbeta repertoire of CD4 T-cell subpopulations among human immunodeficiency virus type 1-infected children and adolescents.

Yin L, Kou ZC, Rodriguez C, Hou W, Goodenow MM, Sleasman JW.

Clin Vaccine Immunol. 2009 Sep;16(9):1293-301. doi: 10.1128/CVI.00074-09. Epub 2009 Jul 15.

PMID:
19605599
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Kolte L, Dreves AM, Ersbøll AK, Strandberg C, Jeppesen DL, Nielsen JO, Ryder LP, Nielsen SD.

J Infect Dis. 2002 Jun 1;185(11):1578-85. Epub 2002 May 17.

PMID:
12023763
[PubMed - indexed for MEDLINE]
Free Article
13.

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB; AIDS Clinical Trials Group 328 Study Team.

Arch Intern Med. 2007 Mar 26;167(6):597-605.

PMID:
17389292
[PubMed - indexed for MEDLINE]
14.

Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.

Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.

Chin Med J (Engl). 2009 Oct 20;122(20):2497-502.

PMID:
20079166
[PubMed - indexed for MEDLINE]
15.

Responsiveness of T cells to interleukin-7 is associated with higher CD4+ T cell counts in HIV-1-positive individuals with highly active antiretroviral therapy-induced viral load suppression.

Camargo JF, Kulkarni H, Agan BK, Gaitan AA, Beachy LA, Srinivas S, He W, Anderson S, Marconi VC, Dolan MJ, Ahuja SK.

J Infect Dis. 2009 Jun 15;199(12):1872-82. doi: 10.1086/598858.

PMID:
19432535
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study).

Cahn P, Ruxrungtham K, Gazzard B, Diaz RS, Gori A, Kotler DP, Vriesema A, Georgiou NA, Garssen J, Clerici M, Lange JM; (BTE) Blinded Nutritional Study for Immunity and Tolerance Evaluation Study Team.

Clin Infect Dis. 2013 Jul;57(1):139-46. doi: 10.1093/cid/cit171. Epub 2013 Mar 19.

PMID:
23511299
[PubMed - indexed for MEDLINE]
Free Article
17.

Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.

Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D, Leong WP, Raffanti SP, Wheeler DA, Anderson RD, Keiser P, Schrader SR, Goodgame JC, Steinhart CR, Murphy RL, Wolin MJ, Smith KA.

HIV Clin Trials. 2000 Nov-Dec;1(3):1-15.

PMID:
11590500
[PubMed - indexed for MEDLINE]
18.

Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation.

Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR.

J Infect Dis. 2010 Oct 15;202(8):1254-64. doi: 10.1086/656369.

PMID:
20812848
[PubMed - indexed for MEDLINE]
Free Article
19.

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.

Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, Goujard C, Rouzioux C, Maral J, Delfraissy JF, Emilie D, Aboulker JP; ANRS 079 Study Group.

AIDS. 2003 Feb 14;17(3):343-51.

PMID:
12556688
[PubMed - indexed for MEDLINE]
20.

A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.

Nanteza MW, Mayanja-Kizza H, Charlebois E, Srikantiah P, Lin R, Mupere E, Mugyenyi P, Boom WH, Mugerwa RD, Havlir DV, Whalen CC.

J Infect Dis. 2011 Sep 15;204(6):884-92. doi: 10.1093/infdis/jir503.

PMID:
21849285
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk